US · HRTX
Heron Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cary, CA 92121
- Website
- herontx.com
Price · as of 2025-12-31
$1.27
Market cap 187.95M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $25.78 | +1,929.92% |
| Intrinsic Value(DCF) | $0.48 | -62.2% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $6.80 | $31.07 | $0.66 | $0.00 | $47.34 |
| 2012 | $11.00 | $627.80 | $2.21 | $0.00 | $0.00 |
| 2013 | $14.43 | $27.29 | |||
| 2014 | $14.62 | ||||
| 2015 | $18.78 | ||||
| 2016 | $14.70 | $0.00 | $0.00 | ||
| 2017 | $22.75 | $319.38 | $2.50 | $0.00 | $0.00 |
| 2018 | $25.74 | $43.37 | $16,324.98 | $0.00 | $0.00 |
| 2019 | $16.52 | $35.15 | $221,897.38 | $0.00 | $0.00 |
| 2020 | $16.94 | $28.07 | $59.73 | $0.00 | $73.52 |
| 2021 | $4.96 | $21.65 | $0.00 | $0.00 | $0.00 |
| 2022 | $2.16 | $23.54 | $0.00 | $0.00 | $0.00 |
| 2023 | $2.60 | $26.52 | $0.00 | $0.00 | $0.00 |
| 2024 | $2.39 | $28.10 | $0.00 | $0.00 | $0.00 |
| 2025 | $1.20 | $25.78 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Heron Therapeutics, Inc.'s (HRTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $25.78
- Current price
- $1.27
- AI upside
- +1,929.92%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.48
-62.2% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| HRTX | Heron Therapeutics, Inc. | $1.27 | 187.95M | +1,930% | -62% | — | — | -9.91 | 13.96 | 1.29 | -16.45 | -28.56 | 13.96 | 73.31% | -1.64% | -13.04% | 209.08% | -2.63% | -8.26% | 9.81 | — | 2.48 | 1.42 | -6.26 | 3468.00% | 736.00% | 1516.00% | -13.95% | -0.29 | -28.89% | 0.00% | 0.00% | 19.98% | -115.86 | -10.54 | 1.90 | -8.88 |
| CHRS | Coherus Oncology, Inc. | $1.67 | 201.81M | +1,660% | -75% | -94% | +75% | 4.18 | -0.90 | 0.45 | 4.32 | — | -0.64 | 55.97% | -41.83% | 10.68% | -17.52% | -122.98% | 5.29% | -2.04 | -4.11 | 1.21 | 0.88 | 2.36 | -10988.00% | 378.00% | -8833.00% | -17.16% | -0.07 | -22.51% | 0.00% | 0.00% | 196.44% | -2.36 | -12.87 | 0.99 | -4.79 |
| EPRX | Eupraxia Pharmaceuticals … | $8.18 | 273.87M | — | — | — | — | -5.48 | 4.23 | — | -3.01 | — | 4.23 | 0.00% | — | — | -144.55% | 1233.17% | -93.26% | 0.00 | -44.74 | 11.10 | 10.74 | 0.92 | -3504.00% | — | 4455.00% | -21.32% | -9.67 | 955.80% | 0.00% | 0.00% | 17.10% | -2.78 | -3.59 | — | 19.45 |
| GNFT | Genfit S.A. | $10.00 | 497.97M | +550% | -76% | -82% | -52% | 103.96 | 2.26 | 2.34 | 16.42 | — | 7.38 | 99.55% | 4.90% | 2.25% | 2.20% | 4.87% | 0.93% | 0.90 | 0.69 | 1.23 | 1.19 | -2.36 | -10517.00% | 13456.00% | -12455.00% | 9.08% | 0.20 | 25.88% | 0.00% | 0.00% | 7.69% | 41.76 | 9.63 | 2.04 | -1.81 |
| IVVD | Invivyd, Inc. | $1.69 | 224.31M | — | — | — | — | -0.70 | 1.77 | 4.72 | -0.30 | — | 1.77 | 93.63% | -696.80% | -669.42% | -138.71% | 1644.29% | -94.75% | 0.02 | — | 1.62 | 1.30 | 0.39 | -2099.00% | — | -181.00% | -142.50% | -2.75 | 1586.23% | 0.00% | 0.00% | 0.00% | -0.29 | -0.30 | 2.04 | -12.54 |
| MDWD | MediWound Ltd. | $17.30 | 187.92M | +19% | -58% | — | — | -5.58 | 5.41 | 8.34 | -4.71 | -1.84 | 5.43 | 8.81% | -95.85% | -149.46% | -96.33% | 446.97% | -43.19% | 0.22 | -34.55 | 1.97 | 1.85 | 0.08 | 30400.00% | 822.00% | 1753.00% | -11.80% | -0.51 | 458.83% | 0.00% | 0.00% | 0.00% | -6.83 | -6.65 | 6.55 | -1.69 |
| NTHI | Neonc Technologies Holdin… | $10.22 | 198.27M | — | — | — | — | — | — | — | — | — | — | 100.00% | -8605.45% | -14335.50% | 122.08% | 110.23% | -508.20% | 0.00 | -2.64 | 0.25 | 0.02 | 0.00 | -2125.00% | 1779.00% | 12414.00% | — | -0.47 | 65.03% | — | 0.00% | — | — | — | — | — |
| OABI | OmniAb, Inc. | $1.72 | 185.11M | +16,336% | +3% | — | +382% | -5.61 | 1.21 | 13.19 | -6.12 | -28.61 | 5.31 | 100.00% | -282.30% | -235.05% | -20.60% | -25.66% | -17.70% | 0.08 | — | 4.52 | 4.29 | 0.09 | 1961.00% | -2275.00% | -600882.00% | -11.94% | -2.63 | -16.47% | 0.00% | 0.00% | 3.92% | -4.18 | -7.51 | 11.81 | 4.59 |
| SLS | SELLAS Life Sciences Grou… | $4.93 | 702.24M | — | — | — | — | -2.36 | 7.69 | — | 94.85 | — | 9.65 | 0.00% | — | — | -4147.88% | 484.07% | -240.78% | 0.11 | — | 1.72 | 1.46 | -20.39 | -6269.00% | — | -409.00% | -48.61% | -3.72 | 543.81% | 0.00% | 0.00% | 15.46% | -1.90 | -1.69 | — | -18.42 |
| TARA | Protara Therapeutics, Inc… | $6.36 | 245.43M | — | — | — | — | -1.86 | 0.50 | — | 1.70 | — | 0.51 | 0.00% | — | — | -37.88% | -1031.24% | -34.25% | 0.03 | — | 15.71 | 15.54 | 3.24 | -3922.00% | — | -460.00% | -43.33% | -3.27 | -752.56% | 0.00% | 0.00% | 150.03% | 1.69 | 2.31 | — | 1.75 |
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
- CEO
- Craig Alexander Collard
- Employees
- 122
- Beta
- 1.25
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.48 ÷ $1.27) − 1 = -62.2% (DCF, example).